AbbVie vs Merck & Co

AbbVie and Merck & Co are two pharmaceutical giants that have long been regarded as top contenders in the industry. AbbVie is known for its blockbuster drug Humira, which has been a consistent revenue generator for the company. On the other hand, Merck & Co has a diverse portfolio of products, including vaccines and treatments for various diseases. Both companies have experienced fluctuations in their stock prices due to factors such as patent expirations and regulatory challenges. Investors should closely monitor developments in the healthcare sector to make informed decisions about investing in AbbVie vs Merck & Co stocks.

AbbVie

Merck & Co

Stock Price
Day Low	$191.22
Day High	$196.18

Year Low	$135.85
Year High	$199.95
Yearly Change	47.18%

Revenue
Revenue Per Share	$31.09
5 Year Revenue Growth	0.45%
10 Year Revenue Growth	1.60%

Profit
Gross Profit Margin	0.72%
Operating Profit Margin	0.27%
Net Profit Margin	0.10%

Stock Price
Day Low	$109.89
Day High	$111.58

Year Low	$99.14
Year High	$134.63
Yearly Change	35.80%

Revenue
Revenue Per Share	$24.67
5 Year Revenue Growth	0.45%
10 Year Revenue Growth	0.58%

Profit
Gross Profit Margin	0.74%
Operating Profit Margin	0.27%
Net Profit Margin	0.22%

AbbVie

Merck & Co

Financial Ratios
P/E ratio	63.57
PEG ratio	4.83
P/B ratio	50.07
ROE	57.35%

Payout ratio	201.82%
Current ratio	0.81
Quick ratio	0.71
Cash ratio	0.31

Dividend
Dividend Yield	3.23%
5 Year Dividend Yield	10.52%
10 Year Dividend Yield	13.98%
AbbVie Dividend History

Financial Ratios
P/E ratio	20.57
PEG ratio	2.10
P/B ratio	6.48
ROE	33.75%

Payout ratio	55.64%
Current ratio	1.47
Quick ratio	1.22
Cash ratio	0.44

Dividend
Dividend Yield	2.76%
5 Year Dividend Yield	8.26%
10 Year Dividend Yield	5.52%
Merck & Co Dividend History

AbbVie or Merck & Co?

When comparing AbbVie and Merck & Co, different investors may prioritize various metrics based on their investment strategies and goals. So, ask yourself what type of investor you are. This will guide you in determining which metrics are most important for your investment decision between AbbVie and Merck & Co.

Dividend Investors:

Dividend investors look for stable and growing income streams, using dividend metrics to assess potential investments. A company's dividend yield essentially measures the size of its dividend relative to the total market value of the company. AbbVie has a dividend yield of 3.23%, while Merck & Co has a dividend yield of 2.76%. Beyond the yield itself, considering the growth and sustainability of these dividends is also crucial. AbbVie reports a 5-year dividend growth of 10.52% year and a payout ratio of 201.82%. On the other hand, Merck & Co reports a 5-year dividend growth of 8.26% year and a payout ratio of 55.64%.

Value Investors:

Value investors focus on financial metrics to determine a stock's intrinsic value compared to its market value. The Price-to-Earnings (P/E) Ratio links stock price to a company's earnings per share, with AbbVie P/E ratio at 63.57 and Merck & Co's P/E ratio at 20.57. Another crucial valuation metric is the Price-to-Book (P/B) Ratio, which compares stock price with book value per share. AbbVie P/B ratio is 50.07 while Merck & Co's P/B ratio is 6.48.

Growth Investors:

Growth investors prioritize metrics indicative of a company's expansion potential. Focusing on top-line growth, AbbVie has seen a 5-year revenue growth of 0.45%, while Merck & Co's is 0.45%. Return on Equity (ROE) measures how effectively a company uses equity investment to generate earnings, with AbbVie's ROE at 57.35% and Merck & Co's ROE at 33.75%.

Retail Investors:

Retail investors often consider stock affordability and company familiarity. For example, day low prices are $191.22 for AbbVie and $109.89 for Merck & Co. Over the past year, AbbVie's prices ranged from $135.85 to $199.95, with a yearly change of 47.18%. Merck & Co's prices fluctuated between $99.14 and $134.63, with a yearly change of 35.80%. Brand recognition also plays a role, as familiarity with a company can influence investment decisions.